Kelsey Pan, Heme/Onc Chief Fellow at MD Anderson Cancer Center, shared a post on X:
“Grateful for the opportunity to work with the incredible Van Morris on this phase I/II trial of encorafenib, cetuximab and nivolumab in patients with BRAF V600E mutated mCRC who progressed on prior treatment with BRAF + EGFR targeted treatment.
While the addition of Nivo did not seem to overcome resistance after progression on prior E+C, there remains a role of E+C+N in the BRAF tx naive population.”